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IntroductIon
Migraine is classified as a primary headache disorder which 
manifests as recurrent painful headache attacks. These attacks 
differ in frequency amongst individuals and also in duration 
ranging from an hour up to even three days. The prevalence 
is higher in females (18%) than in males (6%).1 Generally, the 
onset of migraine is seen at around puberty, with the onset of 
menarche in females, with its effects peaking between the ages of 
35 and 45 and declining thereafter.2
PathoPhysIology 
The pathophysiology of migraines is best described through an 
interaction of vascular and neurogenic theories hence making the 
disorder of neurovascular origin. Thomas Willis described how 
the pain experienced from the headache is a result of vasodilation 
of the meningeal and cerebral arteries.3 It was later established 
that there is an interaction between the brain’s neural activity and 
the mentioned blood vessels. Migraine is known to be associated 
with hypertension, stroke, and a patent foramen ovale, hence 
confirming the role of the vascular system in its pathophysiology.4
In 2013, Amin et al conducted imaging studies during 
spontaneous migraine attacks and concluded that the dilation of 
blood vessels is not the principal cause of central and peripheral 
pain.5 It is the proinflammatory agents as well as neuropeptides 
released from trigeminal nerve afferents within the meninges that 
trigger the pain. This occurs together with the vasodilation via 
sensitization of both the central and peripheral neurons in the 
trigeminovascular system.6 Genetic variability is an important 
component that influences the susceptibility of developing this 
problem, as well as the severity of the symptoms.7
The trigeminal nerve and its fibres innervate a set of intra- an 
extra- meningeal blood vessels and this is what makes up the 
trigmeninovascular system.8 Nerve endings from this system 
innervate both intracranial and extracranial structures such as 
venous sinuses and the eye respectively. During the pain phase 
of the condition the trigeminovascular system is activated and 
initiates a cascade of events from the sensory nerve endings of the 
trigeminal nerve. Vasoactive neuropeptides such as substance P, 
calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-
activating peptide, neurokinin A and nitric oxide are usually stored 
in the trigeminal nerves.9 When released, they lead to vasodilation 
and increased blood flow which result in oedema in the meningeal 
vascular system further worsening the sensation of pain as 
demonstrated in Figure 1.10 Furthermore, upon stimulation of the 
trigeminal nerve system, structural changes of the dura mater have 
been noted including mast cell degranulation as well as changes in 
the postcapillary venules such as platelet aggregation.11 
Another important phenomenon is linked to migraine 
aura; the cortical spreading depression (CSD) was first 
described in 1943 by a Brazilian neurophysiologist.12 This is 
an electrophysiological event described as an intense wave of 
neurological activity within the brain at a rate of 2-5mm/min 
which slowly spreads over cortical brain regions and precedes 
a prolonged period of depressed neural activity as it interferes 
with calcium, potassium and sodium ion gradients.13 It has been 
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proven that CSD activates the trigeminovascular system hence 
contributing to the pain.14 CSD is implicated in visual aura 
where the visual field is affected, starting at the centre and 
spreading to the periphery at a rate of 3mm/min.15
aetIology 
Migraine has a strong genetic component, also stemming 
from the interaction which multiple genes - particularly 
those concerned with neural, vascular, hormonal and 
mitochondrial systems - have with environmental 
factors.7 Genes coding for serotonin and dopamine 
systems have been studied and an association has been 
identified between the human serotonin transporter 
SLC6A4 gene and migraine. The latter gene codes 
for a membrane protein that removes serotonin 
from the synapse and recycles it back into neurons.16 
During a migraine attack, serotonin levels are 
known to be decreased and this leads to neuropeptide 
release. Dopamine’s interaction with its receptors in the 
trigeminovascular system is implicated in the prodromal 
symptoms experienced.17 A range of food items have 
been identified as triggering factors and include 
chocolate, alcohol, cheese and dairy products.18 The 
fact that migraine attacks are more common in 
women post-puberty may be explained by the 
fluctuating levels of female hormones during the 
menstrual cycle which interact with oestrogen and progesterone 
receptors, rendering females more susceptible. Both during 
pregnancy and post-menopause, hormonal levels are relatively 
constant and it is during these times that migraine episodes 
decrease.19 Other known triggering factors include exercise, the 
oral contraceptive pill and variations in the sleep-wake cycle.
symPtoms and sIgns 
The typical presentation of migraines is of a severe unilateral 
headache which may be pulsatile. Nausea, vomiting and 
photophobia are commonly associated features.20 There may 
also be allodynia, lacrimation, ptosis, depression and transient 
amnesia.21 Before a patient experiences the headache, there may 
be a prodrome and an aura which arise from areas in the cortex, 
brainstem, hypothalamus and limbic system. The prodromal phase 
consists of symptoms which precede the headache by several hours 
and include food cravings, irritability, and fatigue.20 The migraine 
aura is a separate phase of a migraine attack consisting of focal 
neurological symptoms which last from five minutes till one hour 
before migraine headache onset and then resolves completely. 
Symptoms and signs may be positive or negative indicating gain-of-
function or loss-of-function respectively. Examples include tremor 
or muscle weakness if the motor cortex is affected or flashing lights 
and scotomas when the somatosensory cortex is involved. Aphasia 
will result if the speech area is affected.22
management  
The non-pharmacological management of migraine includes 
reassessment of the patient’s diet and lifestyle. Therapy sessions 
including relaxation and cognitive behavioural therapy have also 
been proven useful.23 NSAIDs and other simple analgesics, such as 
paracetamol, together with the anti-emetic metoclopramide may 
also be used during an acute migraine episode.24 The more specific 
anti-migraine drugs include ergot and triptan derivatives which 
demonstrate agonistic properties on serotonin receptors and are 
also used in the acute phase. Locally, Zolmitriptan is the triptan 
mostly in use. The release of neurotransmitters from central and 
peripheral trigeminal nociceptive nerve terminals can be inhibited 
by the serotonin-5HT1B/1D receptor agonist zolmitriptan as 
well as ergot alkaloids, and indomethacin.25 Triptans exert their 
effect by causing intracranial vasoconstriction and also reduce 
neuropeptide extravasation.23 Studies have proved the benefit of 
using combinations of NSAIDs and triptans to improve outcome.26 
Although the majority of patients do not require preventive 
medication, this should be considered if the patient’s quality of life 
is significantly affected, if there are frequent attacks and in case of 
unresponsiveness to acute treatment. Amongst the most effective 
and preventive drugs in use is the beta-blocker propranolol which 
has been showed to reduce migraine frequency by more than 50%. 
Tricyclic antidepressants particularly amitriptyline, calcium channel 
blockers including verapamil and flunarizine as well as anti-
epileptic medications such as carbamazepine, gabapentin, valproic 
acid and topiramate are also used.27 Modern treatment under 
development entails the use of humanized monoclonal antibodies 
against CGRP and its receptors which are implicated in the 
pathophysiology of migraine.28 More complex targeted therapy for 
migraine is brain modification; transcranial magnetic stimulation is 
one example where brain excitability is modified.29
conclusIon 
Migraine episodes have consequences on the patient’s quality 
of life as it may interfere with employment, their capability to 
take care of their families and social relationships. This may be 
measured using the Migraine Disability Assessment where higher 
scores are associated with greater levels of disability.30 Given 
the complexity of the condition, research and studies are on the 
increase so as to gather more knowledge and hence be able to 
understand and manage this debilitating disease better. 
Figure 1. During a migraine attack CGRP is released from trigeminal nerve 
afferent fibres both centrally and peripherally. This leads to inflammation and 
vessel dilation. CGRP antibodies block or reduce CGRP levels peripherally 
whilst CGRP antagonists act centrally to suppress the effects of CGRP.
Source: Russell FA et al. Calcitonin Gene-Related Peptide: 
Physiology and Pathophysiology.10 ref
er
en
ce
s c
an
 be
 ac
ce
ss
ed
 on
 th
es
yn
aP
se
.ne
t
7Volume 17, 2018  issue 04
